AKBA

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
AKBA has been the topic of several other reports. BTIG Research decreased their price objective on shares of Akebia Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright decreased their price objective on shares of Akebia Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Thursday. Zacks Research lowered shares of Akebia Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Akebia Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.00.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
AKBA has been the topic of several other reports. BTIG Research decreased their price objective on shares of Akebia Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright decreased their price objective on shares of Akebia Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Thursday. Zacks Research lowered shares of Akebia Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Akebia Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.00.

Akba- Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
AKBA has been the topic of several other reports. BTIG Research decreased their price objective on shares of Akebia Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright decreased their price objective on shares of Akebia Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Thursday. Zacks Research lowered shares of Akebia Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Akebia Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.00.

Akba- stocks do rise in price! Dumb Ass Bear!

Akba- Zacks #2 rating with A VGM rating, hell yeah I’m buying and HODL!

QHY NO Volume?

Same song secong verse, same as yesterdays burst!

Buying more!

??????

$FGEN $AKBA $ZOM $OCGN all gems ? ?